A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/404 (2006.01) A61K 41/00 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2600386
This invention generally relates to Indoloquinone caused tumor radiation therapy sensitization. More specifically, this invention relates to the discovery of indoloquinones as a radiation sensitizer (radiation therapy adjuvant) due to its ability to selectively target hypoxic cells and to damage the DNA of these hypoxic cells. Indoloquinones do so with minimal normal cell and tissue toxicity.
D'une manière générale la présente invention a trait à la sensibilisation à la radiothérapie des tumeurs par l'indoloquinone. De manière plus spécifique, l'invention a trait à la découverte d'indoloquinones en tant qu'agents de sensibilisation à la radiothérapie (adjuvant de radiothérapie) grâce à sa capacité de ciblage sélectif de cellules hypoxiques et à l'endommagement de l'ADN de ces cellules hypoxiques. Les indoloquinones réalisent cet effet avec une toxicité minimale des cellules et tissus normaux.
Burd Randy
Chawla Shanta
Dicker Adam P.
Lenaz Luigi
Reddy Guru
Smart & Biggar
Spectrum Pharmaceuticals Inc.
LandOfFree
Indoloquinone tumor radiation sensitization does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indoloquinone tumor radiation sensitization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indoloquinone tumor radiation sensitization will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1398562